Evidence map›Paper›PMID 31490342›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2019

HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013.

Timothy H Holtz, Anupong Chitwarakorn, James P Hughes, Marcel E Curlin, Anchalee Varangrat, Maoji Li, K Rivet Amico, Philip A Mock, Robert M Grant, Thai HPTN 067/ADAPT Study Team

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Timothy H HoltzThailand Ministry of Public Health-U.S., Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
Anupong ChitwarakornDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
James P HughesDepartment of Biostatistics, University of Washington, Seattle, WA.
Marcel E CurlinThailand Ministry of Public Health-U.S., Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
Anchalee VarangratThailand Ministry of Public Health-U.S., Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
Maoji LiVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
K Rivet AmicoDepartment of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI.
Philip A MockThailand Ministry of Public Health-U.S., Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
Robert M GrantDepartment of Medicine, University of California, San Francisco, CA.
Thai HPTN 067/ADAPT Study Team

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Emory HIV/AIDS Clinical Trials UnitUM1AI069418 · NIAID · EMORY UNIVERSITY · PI Moises Arturo Huaman Joo, Colleen F Kelley · 2012 to 2026
$46.0M
Emory HIV/AIDS Clinical Trials UnitU01AI069418 · NIAID · EMORY UNIVERSITY · PI LENNOX, JEFFREY · 2007 to 2011
$13.9M
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)U01AI047996 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2000 to 2006
$8.4M
NIAID NIH HHS U01 AI047996NIAID NIH HHS U01 AI069418NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069418
6 · The paper itself

Abstract

backgroundWe identified correlates of sex-related pre-exposure prophylaxis (PrEP) adherence in HPTN067/ADAPT, a phase 2, open-label feasibility study of daily and nondaily regimens of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)-based PrEP, among Thai men who have sex with men (MSM), and transgender women (TGW), Bangkok.

methodsParticipants were randomly assigned to one of three self-administered dosing regimens for 24 weeks: daily, time-driven, or event-driven. Demographic and behavioral information was obtained at screening. Pill-container opening was recorded with electronic dose monitoring, and self-reported information on PrEP use, sex events, and substance use was obtained during weekly interviews to confirm dose data. Sex-related PrEP adherence was calculated as the proportion of sex events covered by PrEP use (at least one tablet taken within 4 days before sex and at least one tablet taken within 24 hours after sex) to total sex events. We used multivariate modeling with sex event as the unit of analysis to evaluate correlates associated with sex-related PrEP adherence.

resultsAmong 178 MSM and TGW, sex-related PrEP adherence was similar in the daily and time-driven arms (P = 0.79), both significantly greater than the event-driven arm (P = 0.02 compared to daily). Sex-related PrEP adherence by those reporting stimulant use (74.2%) was similar to those reporting other nonalcohol drug use (76.3%, P = 0.80), but lower than those reporting no substance use (84.6%, P = 0.04). In a multivariable model, randomization to the event-driven arm, a higher prestudy number of reported sex events, and use of stimulant drugs were associated with significantly lower sex-related PrEP adherence.

conclusionAdherence was influenced by treatment schedule and adversely affected by nonalcoholic substance use. Regardless of these factors, Thai MSM and TGW maintained high adherence levels to oral PrEP dosing regimens and coverage of sexual exposures.

Indexed as

Homosexuality, MaleMedication AdherencePre-Exposure ProphylaxisTransgender PersonsAdolescentAdultEmtricitabineFeasibility StudiesFemaleHIV InfectionsHumansMaleTenofovirYoung AdultEmtricitabineTenofovir

Identifiers

PMID31490342
PMCPMC6742570

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.